VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. We develop certified predictive ex vivo 3D tumor testing services for reliable treatment response prediction for the clinic and to improve patient stratification for clinical trials. Our proprietary technology provides highly reproducible drug testing in the native tumor microenvironment (TME).
VitroScan’s clinical trial program is performed in collaboration with expert clinicians from leading oncology centers. In these trials patient specific ex vivo tumor sensitivity to chemo-, targeted, or immunotherapy is correlated to clinical outcomes.
We are dedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients.
Please contact us for more information